Facebook Tracking Image

National Comprehensive Cancer Network

About NCCN

NCCN and Roche Collaborate on Innovative Cancer Research

JENKINTOWN, Pa., October 31, 2005 — The National Comprehensive Cancer Network (NCCN) announced that it has entered into a collaboration with Roche Laboratories, Inc. to develop and review ongoing oncology research protocols and trials examining Xeloda® (capecitabine) in combination with radiologic therapy, and other drugs and biologics in the treatment of solid tumors including esophageal, gastric and pancreatic cancers.

“NCCN’s mission is to improve cancer care by studying and evaluating new and promising treatments and by facilitating research collaborations,” said William T. McGivney, Ph.D., Chief Executive Officer, NCCN. “Financial support from Roche will fund clinical research designed and carried out by investigators at NCCN member institutions – research that may identify treatment advances that can improve both survival and quality of life for patients with difficult-to-treat cancers.”

NCCN will conduct the studies through its Oncology Research Program, which facilitates clinical research by streamlining and centralizing site identification and trial initiation, drawing on the expertise of investigators at NCCN member institutions and helping to establish collaborations with pharmaceutical and biotech companies.

Roche will provide support for nine studies at seven NCCN member institutions including the Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University; Roswell Park Cancer Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Alabama at Birmingham Comprehensive Cancer Center; UCSF Comprehensive Cancer Center; and The University of Texas M.D. Anderson Cancer Center.

“We are pleased to support this important research in collaboration with NCCN,” stated Lars E. Birgerson, M.D., Vice President of Medical Affairs for Roche. “We are committed to not only advancing medical research, but more importantly providing the best possible treatment options for advancing survival for all cancer patients.”

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 30 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world.

The NCCN Member Institutions are:

  • Abramson Cancer Center at the University of Pennsylvania
  • Fred & Pamela Buffett Cancer Center
  • Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
  • City of Hope National Medical Center
  • Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
  • Duke Cancer Institute
  • Fox Chase Cancer Center
  • Huntsman Cancer Institute at the University of Utah
  • Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • Mayo Clinic Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Moffitt Cancer Center
  • The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
  • O'Neal Comprehensive Cancer Center at UAB
  • Roswell Park Comprehensive Cancer Center
  • Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
  • St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
  • Stanford Cancer Institute
  • UC San Diego Moores Cancer Center
  • UCLA Jonsson Comprehensive Cancer Center
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • University of Colorado Cancer Center
  • University of Michigan Rogel Cancer Center
  • The University of Texas MD Anderson Cancer Center
  • University of Wisconsin Carbone Cancer Center
  • UT Southwestern Simmons Comprehensive Cancer Center
  • Vanderbilt-Ingram Cancer Center
  • Yale Cancer Center/Smilow Cancer Hospital